Relation of Plasma Renin Activity to the Antihypertensive Effect of MK 421 in the Rat

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1982 May 1

PMID 6282372

Citations 1

Authors

D Bradshaw

P H Franz

A L Sugden

Affiliations

Soon will be listed here.

Abstract

1 The effect of the angiotensin converting enzyme inhibitor, MK 421 (N-((S)-1-(ethoxycarbonyl)-3-phenylpropyl)L-Ala-L-Pro), on the blood pressure of two-kidney Goldblatt hypertensive rats has been investigated in relation to he initial plasma renin activity (PRA) and the initial blood pressure of the individual animals. 2 Blood pressure was monitored by an indirect tail-cuff method at 1, 3, 6 and 24 h after dosing. MK 421 produced a fall in blood pressure in the majority of animals, but the extent of this reduction varied considerably between individuals. 3 The change in blood pressure showed a significant correlation with both the initial PRA and the initial blood pressures of the animals. However, only a modest correlation was found between the initial PRA and the degree of hypertension. 4 MK 421 (10 mg/kg, orally) produced a mean blood pressure change which was statistically significant (P less than 0.001) at all times tested. 5 It is concluded that the degree of antihypertensive activity of MK 421 is related to the degree of activity of the renin-angiotensin system which, in this model at least, is reflected by the PRA.

Citing Articles

Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Todd P, Heel R Drugs. 1986; 31(3):198-248.

PMID: 3011386 DOI: 10.2165/00003495-198631030-00002.

References

GEROLD M, Tschirky H . Measurement of blood pressure in unanaesthetized rats and mice. Arzneimittelforschung. 1968; 18(10):1285-7. View

Macdonald G, Boyd G, Peart W . Effect of the angiotensin II blocker 1-Sar-8-Ala-angiotensin II on renal artery clip hypertension in the rat. Circ Res. 1975; 37(5):640-6. DOI: 10.1161/01.res.37.5.640. View

Mohring J . Pathogenesis of malignant hypertension: experimental evidence from the renal hypertensive rat. Clin Nephrol. 1975; 4(5):167-74. View

Gavras H, Brunner H, Turini G, KERSHAW G, Tifft C, Cuttelod S . Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978; 298(18):991-5. DOI: 10.1056/NEJM197805042981803. View

Case D, Atlas S, LARAGH J, SEALEY J, Sullivan P, MCKINSTRY D . Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients. Prog Cardiovasc Dis. 1978; 21(3):195-206. DOI: 10.1016/0033-0620(78)90025-7. View

Brunner H, Gavras H, Waeber B, KERSHAW G, Turini G, Vukovich R . Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med. 1979; 90(1):19-23. DOI: 10.7326/0003-4819-90-1-19. View

Swales J . Arterial wall or plasma renin in hypertension?. Clin Sci (Lond). 1979; 56(4):293-8. DOI: 10.1042/cs0560293. View

Bengis R, Coleman T . Antihypertensive effect of prolonged blockade of angiotensin formation in benign and malignant, one- and two-kidney Goldblatt hypertensive rats. Clin Sci (Lond). 1979; 57(1):53-62. DOI: 10.1042/cs0570053. View

Macgregor G, Markandu N, Roulston J, Jones J . Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme. Br Med J. 1979; 2(6198):1106-9. PMC: 1596971. DOI: 10.1136/bmj.2.6198.1106. View

10.

Bravo E, TARAZI R . Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension. 1979; 1(1):39-46. DOI: 10.1161/01.hyp.1.1.39. View

11.

Case D, Atlas S, LARAGH J, Sullivan P, SEALEY J . Use of first-dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response. J Cardiovasc Pharmacol. 1980; 2(4):339-46. DOI: 10.1097/00005344-198007000-00001. View

12.

Brunner H, Gavras H, Waeber B, Textor S, Turini G, Wauters J . Clinical use of an orally acting converting enzyme inhibitor: captopril. Hypertension. 1980; 2(4):558-66. DOI: 10.1161/01.hyp.2.4.558. View

13.

Satoh S, Suzuki M, Satoh H . Hypotensive effect of captopril in relation to plasma renin activity in anesthetized rats. J Pharmacobiodyn. 1980; 3(5):258-60. DOI: 10.1248/bpb1978.3.258. View

14.

Miyamori I, Brown M, Dollery C . Single-dose captopril administration in DOCA/salt rats: reduction of hypotensive effect by indomethacin. Clin Exp Hypertens (1978). 1980; 2(6):935-45. DOI: 10.3109/10641968009037152. View

15.

Sweet C, Gross D, Arbegast P, Gaul S, Britt P, LUDDEN C . Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther. 1981; 216(3):558-66. View